Monday, April 27, 2015 9:14:07 AM
Our lead drug candidate, a small molecule called COTI-2, acts by normalizing the p53 protein function in cancer cells with mutation in the p53 gene. P53 mutations are common in gynecologic cancers with more than 95% of advanced ovarian cancers having this mutation. It appears that of all the ovarian cancer drugs in development at this time, COTI-2 offers the most exciting treatment opportunity. In fact, we believe that COTI-2 may represent a significant potential therapeutic advantage over treatments currently available for ovarian and other gynecologic cancers.
#COTQF / #COT.V
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM